$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000147793224006252 Filed on October 08, 2024

Income Statement

Concept	2024 Q4	2024 Q2	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$196.4K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses			$1.906M
YoY Change			-7.1%
Operating Profit			-$1.906M
YoY Change			-7.1%
Interest Expense			$1.184M
YoY Change			11104.67%
% of Operating Profit
Other Income/Expense, Net			-$1.197M
YoY Change			-76.27%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings			-$3.103M
YoY Change			-56.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	581.2M shares	503.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q4	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$653.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses		$2.931K
Receivables
Other Receivables
Total Short-Term Assets		$664.2K
YoY Change		904.04%
LONG-TERM ASSETS
Property, Plant & Equipment		$3.995K
YoY Change		-27.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$48.79K
YoY Change		-51.67%
TOTAL ASSETS
Total Short-Term Assets		$664.2K
Total Long-Term Assets		$48.79K
Total Assets		$713.0K
YoY Change		326.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$9.325M
YoY Change		38.13%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$9.325M
Total Long-Term Liabilities
Total Liabilities		$9.325M
YoY Change		37.4%
SHAREHOLDERS EQUITY
Retained Earnings		-$26.71M
YoY Change		12.99%
Common Stock		$5.248K
YoY Change		-99.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$5.753M
YoY Change
Total Liabilities & Shareholders Equity		$713.0K
YoY Change		326.65%

Cashflow Statement

Concept	2024 Q4	2024 Q2	2024
OPERATING ACTIVITIES
Net Income			-$3.103M
YoY Change			-56.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities			-$1.430M
YoY Change			21.82%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$8.163K
YoY Change			-95.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$2.030M
YoY Change			448.65%
NET CHANGE
Cash From Operating Activities			-$1.430M
Cash From Investing Activities			-$8.163K
Cash From Financing Activities			$2.030M
Net Change In Cash			$591.5K
YoY Change			-158.89%
FREE CASH FLOW
Cash From Operating Activities			-$1.430M
Capital Expenditures			$0.00
Free Cash Flow			-$1.430M
YoY Change			21.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	usd
CY2024	xeri	Proceeds From Convertible Bridge Loans ProceedsFromConvertibleBridgeLoans	0	usd
CY2024	xeri	Decrease Increase In Fair Value Of Convertible Bridge Loans DecreaseIncreaseInFairValueOfConvertibleBridgeLoans	2448	usd
CY2024Q2	us-gaap	Convertible Debt ConvertibleDebt	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7460414	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8112065	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7460414	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	403117	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3103101	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001481504
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	524853304	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21250000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P11M19D
CY2023	xeri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P1M17D
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	000-54277
CY2024	dei	Entity Registrant Name EntityRegistrantName	XERIANT, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1519178
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	Innovation Centre 1 3998 FAU Boulevard
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 309
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
CY2024	dei	City Area Code CityAreaCode	561
CY2024	dei	Local Phone Number LocalPhoneNumber	491-9595
CY2024	dei	Security12g Title Security12gTitle	Common Stock, $0.00001 par value
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	8200000	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	581184486	shares
CY2024	dei	Auditor Firm AuditorFirmId	6920
CY2024	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	653117	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61625	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4529	usd
CY2024Q2	us-gaap	Notes Receivable Net NotesReceivableNet	8163	usd
CY2023Q2	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	664211	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	66154	usd
CY2024Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	usd
CY2023Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3995	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5507	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32253	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82911	usd
CY2024Q2	us-gaap	Assets Assets	713005	usd
CY2023Q2	us-gaap	Assets Assets	167118	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1211533	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	402568	usd
CY2024Q2	xeri	Due To Related Party Current DueToRelatedPartyCurrent	20000	usd
CY2023Q2	xeri	Due To Related Party Current DueToRelatedPartyCurrent	20000	usd
CY2024Q2	xeri	Shares To Be Issued Current SharesToBeIssuedCurrent	75200	usd
CY2023Q2	xeri	Shares To Be Issued Current SharesToBeIssuedCurrent	75200	usd
CY2024Q2	xeri	Convertible Notes Payable In Default Current ConvertibleNotesPayableInDefaultCurrent	5850000	usd
CY2023Q2	xeri	Convertible Notes Payable In Default Current ConvertibleNotesPayableInDefaultCurrent	5850000	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2132529	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	100000	usd
CY2024Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	247254	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36197	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55999	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9325459	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6751021	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36197	usd
CY2024Q2	us-gaap	Liabilities Liabilities	9325459	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6787218	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	389433144	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	5248	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3894	usd
CY2024Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51950	usd
CY2023Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51950	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20899187	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19789793	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26708915	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23638461	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-5752513	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3792806	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-2859941	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-2827294	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8612454	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6620100	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	713005	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167118	usd
CY2024	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	731128	usd
CY2023	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	1147398	usd
CY2024	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	388000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	353000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	282249	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	280216	usd
CY2024	us-gaap	Professional Fees ProfessionalFees	308109	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	271021	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	196422	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	1905908	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2051635	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-1905908	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2051635	usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19189	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	461842	usd
CY2024	us-gaap	Interest Expense InterestExpense	1183885	usd
CY2023	us-gaap	Interest Expense InterestExpense	10566	usd
CY2024	xeri	Gain Loss Change In Fair Value Of Convertible Bridge Loans GainLossChangeInFairValueOfConvertibleBridgeLoans	-2448	usd
CY2023	xeri	Gain Loss Change In Fair Value Of Convertible Bridge Loans GainLossChangeInFairValueOfConvertibleBridgeLoans	-57368	usd
CY2024	xeri	Loss On Impairment Of Investment LossOnImpairmentOfInvestment	0	usd
CY2023	xeri	Loss On Impairment Of Investment LossOnImpairmentOfInvestment	156460	usd
CY2024	xeri	Gain Loss From Ebenberg Jv GainLossFromEbenbergJv	0	usd
CY2023	xeri	Gain Loss From Ebenberg Jv GainLossFromEbenbergJv	-98781	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20298	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4259987	usd
CY2024	xeri	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	28627	usd
CY2023	xeri	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1197197	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5045004	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7096639	usd
CY2024	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-32647	usd
CY2023	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-29683	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3070454	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7066956	usd
CY2024	xeri	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.01
CY2023	xeri	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.02
CY2024	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	443262234	shares
CY2023	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	339759839	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2961705	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	48000	usd
CY2023	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2023	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	2688128	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	702116	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-7096639	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6620100	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	374906	usd
CY2024	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	-1	usd
CY2024	xeri	Conversion Of Convertible Notes Payable And Accrued Interest Into Common Stock Amount ConversionOfConvertibleNotesPayableAndAccruedInterestIntoCommonStockAmount	669182	usd
CY2024	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	66660	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-3103101	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-3103101	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-7096639	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1512	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1469	usd
CY2024	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	702116	usd
CY2024	xeri	Stock Issued For Services StockIssuedForServices	-374906	usd
CY2023	xeri	Stock Issued For Services StockIssuedForServices	-48000	usd
CY2024	xeri	Change In Fair Value Of Convertible Bridge Loans ChangeInFairValueOfConvertibleBridgeLoans	-2448	usd
CY2023	xeri	Change In Fair Value Of Convertible Bridge Loans ChangeInFairValueOfConvertibleBridgeLoans	-57368	usd
CY2024	xeri	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	28627	usd
CY2023	xeri	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20298	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4259987	usd
CY2024	xeri	Gain Loss On Ebenberg Joint Venture GainLossOnEbenbergJointVenture	0	usd
CY2023	xeri	Gain Loss On Ebenberg Joint Venture GainLossOnEbenbergJointVenture	-98781	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	156460	usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19189	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	461842	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	50658	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	45431	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1598	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3763	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1286773	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	145722	usd
CY2024	xeri	Increase Decrease In Due To Related Party IncreaseDecreaseInDueToRelatedParty	0	usd
CY2023	xeri	Increase Decrease In Due To Related Party IncreaseDecreaseInDueToRelatedParty	-2000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55999	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-48964	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1430345	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1174190	usd
CY2024	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	139947	usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	usd
CY2024	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	131784	usd
CY2023	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
CY2024	xeri	Payments To Acquire Investment In Joint Venture PaymentsToAcquireInvestmentInJointVenture	0	usd
CY2023	xeri	Payments To Acquire Investment In Joint Venture PaymentsToAcquireInvestmentInJointVenture	197563	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2567	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8163	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200130	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2030000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	370000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2030000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	370000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	591492	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1004320	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61625	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1065945	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	653117	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61625	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	669182	usd
CY2023	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	0	usd
CY2024	xeri	Warrants Issued With Convertible Notes Payable Extinguishment WarrantsIssuedWithConvertibleNotesPayableExtinguishment	66660	usd
CY2023	xeri	Warrants Issued With Convertible Notes Payable Extinguishment WarrantsIssuedWithConvertibleNotesPayableExtinguishment	2688128	usd
CY2024	us-gaap	Development Costs DevelopmentCosts	5500000	usd
CY2024	xeri	Preorders And Reservations Amount PreordersAndReservationsAmount	7000000000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26708915	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3103101	usd
CY2024Q2	xeri	Working Capital Deficit WorkingCapitalDeficit	-8661248	usd
CY2024	xeri	Reclassification Policy Textblock ReclassificationPolicyTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain amounts included in prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s previously reported financial statements.</p>
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	156460	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	702116	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	196422	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	4854	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	23348	usd
CY2024	xeri	Warrants Issued WarrantsIssued	118968828	shares
CY2023	xeri	Warrants Issued WarrantsIssued	104802161	shares
CY2024	xeri	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableStock	21250000	shares
CY2023	xeri	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableStock	21250000	shares
CY2024	xeri	Stock Issued During Period Convertible Notes Payable StockIssuedDuringPeriodConvertibleNotesPayable	882527009	shares
CY2023	xeri	Stock Issued During Period Convertible Notes Payable StockIssuedDuringPeriodConvertibleNotesPayable	62283909	shares
CY2024	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	705895000	shares
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	757395000	shares
CY2024	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1728640837	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	945731070	shares
CY2024	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.10	pure
CY2024Q2	xeri	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	220448	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	220448	usd
CY2024Q2	xeri	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	-188195	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	-137537	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32253	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82911	usd
CY2024Q2	xeri	Office Leas Operating Lease Liability OfficeLeasOperatingLeaseLiability	36197	usd
CY2023Q2	xeri	Office Leas Operating Lease Liability OfficeLeasOperatingLeaseLiability	92196	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36197	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55999	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36197	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	37112	usd
CY2024Q2	xeri	Total Future Minimum Lease Payments TotalFutureMinimumLeasePayments	37112	usd
CY2024Q2	xeri	Present Value Discount PresentValueDiscount	-915	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	36197	usd
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5850000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5850000	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	50000	usd
CY2024	us-gaap	Interest Expense Debt InterestExpenseDebt	1070729	usd
CY2023Q4	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	200115	usd
CY2023Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	20011500	shares
CY2024Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	227067	usd
CY2024Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	22706700	shares
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	643546	usd
CY2024Q2	xeri	Exercise Price ExercisePrice	0.09
CY2024Q2	xeri	Convertible Notes Payable Aggregate Face Value ConvertibleNotesPayableAggregateFaceValue	2700000	usd
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.01
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20298	usd
CY2024Q2	xeri	Loans Fair Value LoansFairValue	249702	usd
CY2024Q2	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	2180000	usd
CY2023Q2	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	100000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	47471	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2024Q2	xeri	Convertible Notes Payable Net ConvertibleNotesPayableNet	2132529	usd
CY2023Q2	xeri	Convertible Notes Payable Net ConvertibleNotesPayableNet	100000	usd
CY2024Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	220000	usd
CY2024	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	22000	usd
CY2024	xeri	New Warrant To Purchase Shares Of Common Stock NewWarrantToPurchaseSharesOfCommonStock	23200000	shares
CY2024	us-gaap	Debt Instrument Convertible Conversion Price Decrease DebtInstrumentConvertibleConversionPriceDecrease	0.01
CY2024	us-gaap	Derivative Term Of Contract DerivativeTermOfContract	P3Y
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	247254	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	0	usd
CY2023	xeri	Proceeds From Convertible Bridge Loans ProceedsFromConvertibleBridgeLoans	189886	usd
CY2023	xeri	Decrease Increase In Fair Value Of Convertible Bridge Loans DecreaseIncreaseInFairValueOfConvertibleBridgeLoans	57368	usd
CY2024	xeri	Reclassified From Fair Value To Straight Debt ReclassifiedFromFairValueToStraightDebt	-249702	usd
CY2023	xeri	Reclassified From Fair Value To Straight Debt ReclassifiedFromFairValueToStraightDebt	0	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	247254	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	524853304	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	389433144	shares
CY2024	xeri	Conversion Of Principal Amount ConversionOfPrincipalAmount	220000	usd
CY2024	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	22000	usd
CY2024	xeri	Common Stock Share Issued For Conversion CommonStockShareIssuedForConversion	23200000	shares
CY2024	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	427182	usd
CY2024	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	42718200	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024	xeri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Terms89 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageRemainingContractualTerms89	P1Y9M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2023	xeri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Terms89 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageRemainingContractualTerms89	P0Y11M19D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y1M17D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21250000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.12
CY2024	xeri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P0Y1M17D
CY2024	xeri	Current Tax Rate Of Deffered Tax Assets CurrentTaxRateOfDefferedTaxAssets	0.21	pure
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8112065	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	651651	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1600005	usd
CY2024	dei	Auditor Name AuditorName	Accell Audit and Compliance, P.A

Files In Submission

Name	View Source	Status
0001477932-24-006252-index-headers.html	Edgar Link	pending
0001477932-24-006252-index.html	Edgar Link	pending
0001477932-24-006252.txt	Edgar Link	pending
0001477932-24-006252-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20240630.xsd	Edgar Link	pending
xeri_10k.htm	Edgar Link	pending
xeri_10kimg1.jpg	Edgar Link	pending
xeri_10kimg10.jpg	Edgar Link	pending
xeri_10kimg11.jpg	Edgar Link	pending
xeri_10kimg8.jpg	Edgar Link	pending
xeri_10kimg9.jpg	Edgar Link	pending
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending
xeri-20240630_cal.xml	Edgar Link	unprocessable
xeri-20240630_pre.xml	Edgar Link	unprocessable
xeri-20240630_def.xml	Edgar Link	unprocessable
xeri-20240630_lab.xml	Edgar Link	unprocessable
xeri_10k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2024 Q4 Form 10-K Financial Statement

#000147793224006252 Filed on October 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2024 Q4 Form 10-K Financial Statement

#000147793224006252 Filed on October 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri